NIQ Signs Definitive Agreement to Acquire Gastrograph AI Further Enhancing CPG Innovation Through AI-Driven Data, Platforms, and Capabilities
NielsenIQ (NIQ), a leader in consumer intelligence, today announced it has reached an agreement to acquire Gastrograph AI, a market leading discovery and inquiry platform for sensory insights. The acquisition further strengthens NIQ’s AI capabilities and competitive differentiation to provide CPG companies with the Full View™ of consumer behavior.
Gastrograph AI supports some of the largest consumer brands in the world, utilizing predictive AI to develop, test, and reformulate products by modeling human sensory perception of flavor, aroma, and texture. By integrating Gastrograph AI’s robust sensory database of consumer preferences within NIQ’s ecosystem, we will enable clients to create ideas, enhance concepts, and deliver product formulations that delight consumers. With its AI-enabled capabilities, NIQ’s solutions allow clients to achieve greater speed to market at lower costs.
“Combining Gastrograph AI with NIQ’s AI platform will empower the world’s most influential consumer packaged goods brands in getting to market faster, with better products, and win share more quickly,” said Ramon Melgarejo, President of Strategic Analytics & Insights at NIQ. “In today’s environment, understanding what consumers will buy and why, and being able to act on those insights has never been more important.”
NIQ has been collaborating with Gastrograph AI as it builds BASES Creative Product AI, and the partnership has demonstrated that using AI for product formulation research resonates strongly with the largest global brands. The Gastrograph AI acquisition will enable NIQ to further enhance its AI capabilities in Product Development, building on its Creative Product AI solution launched in 2022.
NIQ’s holistic approach to consumer insights empowers clients to innovate rapidly, connect to consumers, grow and win. Leveraging expertise across NIQ Strategic Analytics & Insights ensures clients receive tailored solutions and insights to address their unique challenges.
About NIQ
NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together two industry leaders with unparalleled global reach. Our global reach spans over 90 countries covering approximately 85% of the world's population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
For more information, please visit www.niq.com
About Gastrograph AI
Gastrograph AI, based in New York City, developed one of the first artificial intelligence solutions designed specifically for predictive product development in the CPG industry. The Gastrograph AI platform efficiently models human sensory perception to understand consumer preferences for multiple demographics and countries and provides market and formulation insights that drive brand success for CPG clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407908345/en/
Contacts
Media:
Sweta Patra
Sweta.patra@nielseniq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug8.4.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma developing the first potential disease-modifying drug (DMOAD) for knee osteoarthritis, announces that it has been awarded €7.6 million in funding under the France 2030 plan to accelerate the clinical development of its lead candidate, 4P004, currently in a Phase 2a trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407335930/en/ France 2030 is a highly selective and strategic initiative by the French government designed to fast-track the next generation of breakthrough innovations. 4MB's selection is a significant endorsement, granted through a rigorous, multi-stage evaluation process by leading scientific, clinical, and technological experts. This recognition highlights the robust scientific foundations of the 4P004 program and its potential to deliver a truly transformative therapy for OA's unmet medical need and significant socio-economic impact with over 600 million pe
BTS Group Invests in ZIM to Expand into Global eSIM Connectivity Solutions8.4.2025 07:00:00 EEST | Press release
BTS Group, a leading investor in global communications and technology, has announced a strategic investment inZIM Connections(ZIM), a gateway to global eSIM connectivity for businesses and consumers worldwide. This investment establishes a collaboration between BTS, a leading global provider, technology enabler, and trusted partner to CommTech players owned by BTS Group, and ZIM, a frontrunner in global eSIM solutions. By leveraging the complementary strengths of both companies, this partnership will drive enhanced global connectivity solutions through eSIM technology for operators and end users. “The global eSIM market is experiencing remarkable growth, with projections estimating an increase from $4.8 billion in 2023 to $34.6 billion by 2033*. With smartphone eSIM adoption expected to reach 76% by 2030**, this investment represents a strategic move into one of the fastest-growing segments in telecom,” said Rafael Olloqui, CEO and Co-Founder of BTS Group.“As global travel and eSIM ado
Wine Institute Responds to Administration’s Latest Trade Action and Ongoing Canadian Ban7.4.2025 22:21:00 EEST | Press release
Today, Wine Institute released the following statement from President and CEO Robert P. Koch in response to the administration’s announcement of new reciprocal tariffs affecting numerous trade partners, including those involved in the import and export of wine with the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407422670/en/ “This isn’t just about trade. It’s about people, livelihoods and an agricultural success story built over generations. When our industry is disrupted, the impact reaches far beyond the winery...” - Robert P. Koch, President & CEO, Wine Institute Wineries across the country continue to suffer economic harm from Canada’s total ban on U.S. wine sales. Since early March, wine, beer and spirits have been the only U.S. products completely barred from entering and being sold in the Canadian market. Prior to these actions, Canada accounted for 35% of all U.S. wine exports, with a retail val
Type One Energy Begins Testing Advanced Fusion Magnet for Stellarators7.4.2025 20:32:00 EEST | Press release
Type One Energy announced today that early results from its testing campaign confirm the essential design elements of the company’s groundbreaking high temperature superconducting (HTS) magnet for use in stellarators. Powerful, modular, HTS magnets for use in modern stellarator machines are an essential feature of the characteristics which make this technology today’s lowest-risk, shortest-path approach to commercially viable fusion energy. The company successfully conducted an accelerated 18-month development program for the world’s most advanced modular HTS stellarator magnets. This program was based on the company’s access to the proven Massachusetts Institute of Technology’s (MIT) VIPER technology for HTS cables in stellarator fusion magnets, for which it indirectly received exclusive rights via a sub-license from Commonwealth Fusion Systems (CFS), as previously announced on February 11th, 2025. With strong technical leadership from Type One Energy co-founder and Engineering Fellow
European Commission Approves Expanded Label for KAFTRIO ® in Combination With Ivacaftor for People With Cystic Fibrosis7.4.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (CF). With this approval, the indication has been expanded to include all patients ages 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator (CFTR) gene. “We have been working for years to bring treatment options to all people with cystic fibrosis, including those with ultra rare mutations,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “We are pleased that the European Commission has broadened the KAFTRIO indication to include all CF patients 2 years and older who have at least one non-class I mutation, ensuring that even more people living with CF can benefit from this transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom